Vidac Pharma is positioning itself as an innovator with two highly interesting projects: The systemic agent VDA-1275 shows synergistic effects with chemotherapies in preclinical studies. In colorectal cancer models, the combination with Cisplatin reduced tumor size by around 39%. This could lead to reduced chemotherapy dosages and fewer side effects. At the same time, VDA-1102 stands out: Originally developed as an ointment for skin cancer, the newly formulated subcutaneous variant crosses the blood-brain barrier, leading to initial successes in pediatric brain tumors. The aim is to exploit the Warburg effect, a metabolic mechanism that could enable new cancer therapies.
News & Events